At 6.1% CAGR, Middle East & Africa Coagulation Market is Projected to be Worth US$ 467.78 Million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa coagulation market was valued at US$ 291.47 million in 2022 and is expected to reach US$ 467.78 million by 2030, registering a CAGR of 6.1% from 2022 to 2030. Rising prevalence of cardiovascular diseases and increasing prevalence of blood disorders are among the critical factors attributed to the Middle East & Africa coagulation market expansion.

According to the Global Hemophilia Care 2020 study, 393,658 bleeding disorders cases have been recognized and documented worldwide over time, including 241,535 hemophilia cases, 87,729 von Willebrand disease cases, and 64,394 other bleeding disorder cases. Therefore, the rising prevalence of blood disorders drives the coagulation market growth.

A coagulation analyzer is a device that measures and evaluates the speed of clot formation or clot coagulation. It provides a fast, simple way to accurately measure blood platelet levels and thrombin and thromboplastin levels. According to the Annual Global Survey 2020 conducted by the World Federation of Hemophilia, around 347,026 people had bleeding disorders, and about 209,614 people were living with hemophilia. This included 165,379 with Hemophilia A, 33,076 with Hemophilia B, 11,159 with Hemophilia type unknown, 84,197 with von Willebrand disease, and 53,215 with other bleeding disorders. Furthermore, individuals from the Middle East can also be affected by sickle cell trait. Over 100 million individuals globally possess the sickle cell trait. Sickle cell disease is one of the most common inherited blood disorders. Thus, the rising prevalence of blood disorders is driving the coagulation market.

On the contrary, high costs associated with coagulation analyzers hampers the growth Middle East & Africa coagulation market.

Based on disease indication, the Middle East & Africa coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von Willebrand’s disease, and others. The liver disease segment held 54.2% share of the Middle East & Africa coagulation market in 2022, amassing US$ 158.02 million. It is projected to garner US$ 250.26 million by 2030 to expand at 5.9% CAGR during 2022–2030.

Based on type, the Middle East & Africa coagulation market is bifurcated into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzers segment held 66.0% share of the Middle East & Africa coagulation market in 2022, amassing US$ 192.46 million. It is projected to garner US$ 294.21 million by 2030 to expand at 5.4% CAGR during 2022–2030. Clinical laboratory analyzers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Middle East & Africa coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 65.1% share of the Middle East & Africa coagulation market in 2022, amassing US$ 189.83 million. It is projected to garner US$ 300.93 million by 2030 to expand at 5.9% CAGR during 2022–2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Middle East & Africa coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 60.7% share of Middle East & Africa coagulation market in 2022, amassing US$ 176.97 million. It is projected to garner US$ 286.78 million by 2030 to expand at 6.2% CAGR during 2022–2030.

By end user, the Middle East & Africa coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held 60.2% share of Middle East & Africa coagulation market in 2022, amassing US$ 175.41 million. It is projected to garner US$ 285.61 million by 2030 to expand at 6.3% CAGR during 2022–2030.

Based on country, the Middle East & Africa coagulation market is categorized into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. Saudi Arabia held 34.6% share of Middle East & Africa coagulation market in 2022, amassing US$ 100.73 million. It is projected to garner US$ 164.34 million by 2030 to expand at 6.3% CAGR during 2022–2030.

Key players operating in the Middle East & Africa coagulation market are Siemens Healthineers AG; ImproGen Diagnostik Kimya San & Tic Ltd Şti; Sysmex Corp; F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Transasia Bio-Medicals Ltd; and Horiba Ltd, among others.

• In Feb 2021, Siemens Healthineers and Sysmex Extend Hemostasis Agreement. Siemens Healthineers and Sysmex Corporation announced the renewal of the companies' long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers will distribute the new Sysmex CN Systems.
• In Aug 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com